thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Antibody Engineering questions

Question 20 of 20 Advanced Scenario

Which trade-offs appear when optimizing affinity, developability and manufacturability together?

Short answer

Pushing affinity often adds charge and hydrophobicity in the binding loops, which brings aggregation, stickiness and viscosity problems. Developability assessment measures those early, so a slightly weaker but well-behaved candidate often beats the tightest binder.

Why

Affinity maturation optimizes one number, and the molecule pays elsewhere. The developability literature notes that repeated rounds of phage selection yield high-affinity molecules but can build up excessive charge or hydrophobicity in the binding loops, leading to reduced solubility, increased hydrophobicity and nonspecific binding that shortens half-life. Yeast display maturation has a similar effect on hydrophobicity, aggregation rate and self-interaction.

The practical answer is to measure these alongside affinity rather than after. A core panel covers thermal unfolding, charge and hydrophobicity, self-interaction, which usually tracks with viscosity at high concentration, aggregation and sub-visible particles, and polyspecificity. Sequence liabilities are cheaper still: free cysteines, unwanted glycosylation motifs and deamidation motifs such as asparagine followed by glycine, especially in the binding loops where a modification would change binding.

Expression titer and purity profile matter too, because a molecule that expresses poorly or assembles badly raises cost and risk. Target biology sets the limit on how much affinity can be traded, since a molecule with too weak an affinity will not occupy its target at achievable doses.

How to work it through

  1. Define the affinity actually required from target levels, dose and mechanism, rather than maximizing it.
  2. Screen sequences in silico for liabilities such as free cysteines, glycosylation motifs and deamidation motifs in the loops.
  3. Run a core developability panel on all leads: thermal stability, hydrophobicity, charge, self-interaction and polyspecificity.
  4. Stress the leads with temperature and pH and measure aggregation afterwards.
  5. Check expression titer and purity on the same candidates.
  6. Rank candidates on the whole profile, and fix single liabilities by targeted substitution before dropping a lead.

An example

Three matured variants bind at 0.2, 0.9 and 3 nM. The tightest binder has two extra hydrophobic residues in a loop, shows strong self-interaction and aggregates after thermal stress. The 0.9 nM variant has a deamidation motif in a loop, removed by a single substitution with no loss of binding, and a clean developability profile.

Modeling shows 0.9 nM is enough for the required occupancy, so that variant is taken forward.

Where the answer stops holding

In vitro developability assays predict risk rather than outcome, and some molecules with poor scores still succeed. The required affinity depends on target density and turnover, which are often uncertain early. Fixing one liability can create another, so each change needs re-testing.

A strong answer covers

  • Affinity maturation tends to add charge and hydrophobicity in the loops
  • Self-interaction predicts viscosity at high concentration
  • Sequence liabilities in the binding loops matter most
  • Define the affinity needed rather than maximizing it
  • Rank candidates on the whole profile, including titer

Common mistakes

  • Selecting the tightest binder and discovering formulation problems later
  • Treating developability as a late checkpoint rather than a selection criterion
  • Removing a sequence liability without re-measuring binding and stability